SEC filing · 8-K

BlossomHill Therapeutics, Inc.: Quarterly results

BlossomHill Therapeutics reported its second quarter 2026 financial results and clinical pipeline updates.

Filed September 18, 2026

Mixed for the company

What happened

Net loss for the second quarter of 2026 was $23.8 million, compared with $13.2 million for the same period in 2025.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to BlossomHill Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.